Detection method of uroschesis capsule
Through network pharmacological analysis and high-performance liquid chromatography detection, the problem of detecting active ingredients of traditional Chinese medicine in Huangcishu Capsules was solved, and the accurate determination and quality control of 8 drug-effective active ingredients was achieved, ensuring the efficacy and safety of the capsules .
Patent Information
- Application Number
- CN202411016765.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-12
AI Technical Summary
It is difficult for the prior art to comprehensively detect the active ingredients and their content in Huangcishu Capsu capsules, which will affect its quality control and efficacy verification.
The 8 pharmaceutical active ingredients in the Yongci Shu Capsu capsule were determined by using network pharmacological analysis methods combined with high performance liquid chromatography detection (succinic acid, arachidonic acid, isobacterium cerevisiae, acacia, kaempferol, and quercetin. , ivyin and β-sitosterol), their mass content is calculated by gradient elution and linear regression equations.
The accurate determination of the active ingredients of the pharmacodynamic active ingredients of the Chingshu Capsu capsule is achieved, reliable quality control indicators are provided, and the efficacy and safety of the capsule are ensured.
Smart Images

Figure CN118937517A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug analysis, and particularly relates to a detection method for Longbishu capsules. Background Art
[0002] Benign prostatic hyperplasia (BPH) is a common urological disease that causes urination disorders in middle-aged and elderly men. Statistics show that the incidence of BPH in men aged 60 is greater than 50%, and it reaches more than 80% at the age of 80. BPH is mainly manifested by histological hyperplasia of prostate stroma and glandular components, anatomical enlargement of the prostate, urodynamic bladder outlet obstruction and lower urinary tract symptoms (LUTS). The disease is characterized by frequent urination, urgency, and frequent urination at night, which seriously affects the patient's sleep quality and daily activities. Regarding the pathogenesis of BPH, there are several hypotheses in the discipline: autoimmune inflammation, urothelial integrity and functional defects, occult prostate infection, urination dysfunction, pelvic floor muscle spasm / pain, neuroendocrine disorders, peripheral / central nervous sensitization, neural remodeling, social and psychological conditions and genetic factors. Some researchers have also proposed that prostate microenvironment disorder, that is, local prostate microenvironment disorder caused by the combined effects of immune disorders, oxidative stress (OS), and pain factor release may be an important pathogenesis of BPH.
[0003] At present, the main treatments for BPH patients are surgical resection and drug therapy. Among them, surgical treatments include bipolar urethral plasma resection of the prostate (TUPKP) and urethral plasma enucleation of the prostate (TUKEP). Both surgical treatments have postoperative complications: urinary incontinence is about 1-2.2%, retrograde ejaculation is about 65-70%, and urethral stenosis is about 3.8%. Commonly used Western medicines for the treatment of BPH are α1-receptor blockers and 5α-reductase inhibitors. Among them, α1-receptor blockers are commonly used drugs for patients with prostatic hyperplasia with moderate and severe lower urinary tract symptoms: including doxazosin, terazosin, and tamsulosin. 5α-reductase is a reductase that converts testosterone to dihydrotestosterone. Dihydrotestosterone has a certain role in benign prostatic hyperplasia. The use of 5α-reductase inhibitors can inhibit hyperplasia to a certain extent. Commonly used drugs include: finasteride and dutasteride. Common side effects of long-term use of this type of drug include dizziness, headache, fatigue, drowsiness, postural hypotension, abnormal ejaculation, etc. In view of the limitations of surgery itself and the serious side effects of existing Western medicine treatments, Chinese patent medicines have become the preferred way to treat BPH.
[0004] TCM believes that BPH belongs to the category of "spermia", "urinary retention" and "stranguria syndrome". There are many records of stranguria in ancient Chinese medical books. "Suwen·Wuchang Zhengdalun" states: "The disease of stranguria is caused by evil damaging the kidney." "Lingshu Jing·Benshu" says: "The triple burner... if it is full, it will cause stranguria, and if it is empty, it will cause nocturnal emission." "Suwen·Xuanming Wuqi" records: "Urinary bladder dysfunction is stranguria, and nocturnal emission." "Suwen·Biaobenbingchuanlun" believes that "bladder disease leads to urinary retention" (Zhang Chunhe, 2016). TCM believes that the etiology and pathogenesis of BPH are closely related to factors such as kidney deficiency and weak qi, blood stasis, dampness and heat. TCM emphasizes syndrome differentiation and treatment, and the treatment should be to activate blood circulation and remove blood stasis, promote dampness and relieve stranguria, and tonify the kidney. Developing and finding convenient, effective and low-toxic Chinese patent medicines is an urgent task for the treatment of BPH.
[0005] Longbishu Capsule is a clinically effective pure Chinese medicine compound preparation based on TCM theory, experience and decades of clinical application. It is a national new drug for the treatment of prostatic hyperplasia. Previous clinical studies of the drug have also confirmed this indication. Longbishu Capsule is composed of six Chinese medicinal materials, including Psoralea Corylifolia Linn, LygodiiSpora, Ambrum, LysimachiaeHerba, PseudobulbusCremastrae Seu Pleiones and LeonuriHerba. It has the effects of promoting blood circulation and removing blood stasis, clearing heat and relieving stranguria. Longbishu Capsule has a clear clinical efficacy in the treatment of prostatic hyperplasia, but its pharmacodynamic material basis, that is, the type of pharmacologically active ingredients of Longbishu Capsule, is not clear, and the detection method of the active ingredient content in Longbishu Capsule is not comprehensive. Summary of the invention
[0006] The purpose of the present invention is to provide a detection method for Longbishu Capsules. The detection method provided by the present invention determines the type of pharmacologically active ingredients of Longbishu Capsules and provides a detection method for the content of pharmacologically active ingredients of Longbishu Capsules, which can be used as a quality control indicator for Longbishu Capsules.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] The present invention provides a method for detecting Longbishu capsules, comprising the following steps:
[0009] According to the effective chemical components of the six traditional Chinese medicines constituting the Longbishu Capsule, a network pharmacology analysis method was used to obtain a network pharmacology map of the compound traditional Chinese medicine of the Longbishu Capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the Longbishu Capsule, eight pharmacologically active ingredients of the Longbishu Capsule were obtained, and the eight pharmacologically active ingredients were succinic acid, arachidonic acid, isorhamnetin, acacetin, kaempferol, quercetin, hederin and β-sitosterol.
[0010] Extracting the Longbishu capsule with a polar solvent, removing the solvent from the obtained extract to obtain a sample to be tested;
[0011] Dissolving the sample to be tested in an alcohol-water solvent to obtain a sample solution to be tested;
[0012] The sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to the eight pharmacologically active ingredients in the Longbishu Capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass contents of the eight pharmacologically active ingredients in the Longbishu Capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentrations and peak areas of the eight pharmacologically active ingredients;
[0013] The conditions for the HPLC detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.2 v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; gradient elution is adopted, and the procedure of the gradient elution is:
[0014] Retention time, minutes Mobile phase A, v:v% Mobile phase B, v:v% 0 10 90 2 15 85 5 16 84 8 20 80 9 45 55 10 10 90 .
[0015] Preferably, the conditions for the HPLC detection also include: a column temperature of 30°C, a flow rate of the mobile phase of 1 mL·min -1 .
[0016] Preferably, the conditions for the HPLC detection also include: a detection wavelength of 280 nm.
[0017] Preferably, the alcohol-water solvent for dissolving the sample to be tested is a methanol-water solution, and the mass percentage of methanol in the methanol-water solution is 80 wt %.
[0018] Preferably, in the liquid chromatography detection, the injection volume of the sample solution to be tested is 5 μL.
[0019] Preferably, the polar solvent used for the extraction is a low-carbon alcohol or a low-carbon alcohol aqueous solution, the low-carbon alcohol includes methanol or ethanol, and the low-carbon alcohol aqueous solution includes a methanol aqueous solution or an ethanol aqueous solution; the mass percentage of the low-carbon alcohol in the low-carbon alcohol aqueous solution is 80%.
[0020] Preferably, the solid-liquid ratio of the Longbishu capsule to the polar solvent is 1:(15-20); the extraction is carried out under heating reflux conditions or under ultrasonic conditions.
[0021] Preferably, the method for obtaining the linear fitting curve and the linear regression equation of the mass concentration and peak area of the eight pharmacologically active ingredients comprises the following steps:
[0022] Dissolving 8 pharmacologically active ingredients in alcohol-water solvents respectively to obtain a series of standard solutions of 8 pharmacologically active ingredients with different mass concentrations respectively, subjecting the series of standard solutions of 8 pharmacologically active ingredients with different mass concentrations to high performance liquid chromatography detection respectively to obtain a series of liquid chromatograms of different mass concentrations corresponding to the 8 pharmacologically active ingredients respectively, and obtaining the liquid chromatographic retention times and linear ranges of 8 pharmacologically active ingredients from the series of liquid chromatograms of different mass concentrations corresponding to the 8 pharmacologically active ingredients respectively;
[0023] A series of mixed standard solutions with different mass concentrations are subjected to high performance liquid chromatography to obtain liquid chromatograms of a series of mixed standard solutions with different mass concentrations, wherein the mixed standard solutions include 8 pharmacologically active ingredients and an alcohol-water solvent; a linear fitting curve of mass concentrations and peak areas of the 8 pharmacologically active ingredients in the mixed standard solutions is obtained from the mass concentrations of the 8 pharmacologically active ingredients in the series of mixed standard solutions with different mass concentrations, the liquid chromatograms of the mixed standard solutions, and the liquid chromatographic retention times of the 8 pharmacologically active ingredients;
[0024] The linear regression equations of the mass concentrations and peak areas of the eight pharmacologically active ingredients in the mixed standard solution were obtained from the linear fitting curves of the mass concentrations and peak areas of the eight pharmacologically active ingredients in the mixed standard solution.
[0025] Preferably, the linear regression equation of the mass concentration and peak area of the eight pharmacologically active ingredients in the mixed standard solution includes:
[0026] The linear regression equation of the mass concentration and peak area of succinic acid is shown in Formula 1:
[0027] Y = 22450X + 5 Formula 1;
[0028] The linear regression equation of the mass concentration and peak area of arachidonic acid is shown in Formula 2:
[0029] Y = 11447X-10 Formula 2;
[0030] The linear regression equation of the mass concentration and peak area of isorhamnetin is shown in Formula 3:
[0031] Y = 10985X + 4 Formula 3;
[0032] The linear regression equation of the mass concentration and peak area of acacetin is shown in Formula 4:
[0033] Y = 11327X + 7 Formula 4;
[0034] The linear regression equation of the mass concentration and peak area of kaempferol is shown in Formula 5:
[0035] Y = 13854X-13 Formula 5;
[0036] The linear regression equation of the mass concentration and peak area of quercetin is shown in Formula 6:
[0037] Y = 12854X + 2 Formula 6;
[0038] The linear regression equation of the mass concentration and peak area of the ivy extract is shown in Formula 7:
[0039] Y=9793.5X-6 Formula 7;
[0040] The linear regression equation of the mass concentration and peak area of the β-sitosterol is shown in Formula 8:
[0041] Y = 21267X + 11 Formula 8;
[0042] In Formulas 1 to 8: X represents the mass concentration of succinic acid, the mass concentration of arachidonic acid, the mass concentration of isorhamnetin, the mass concentration of acacetin, the mass concentration of kaempferol, the mass concentration of quercetin, the mass concentration of hederin, and the mass concentration of β-sitosterol in the mixed standard solution, respectively;
[0043] In Formulas 1 to 8, Y represents the peak area of succinic acid, the peak area of arachidonic acid, the peak area of isorhamnetin, the peak area of acacetin, the peak area of kaempferol, the peak area of quercetin, the peak area of hederin, and the peak area of β-sitosterol in the liquid chromatogram of the mixed standard solution, respectively.
[0044] Preferably, the chromatographic column used in the high performance liquid chromatography is a reverse phase C-18 column; the length of the chromatographic column is 100 mm, the inner diameter is 4.6 mm, and the size of the filler is 1.8 μm.
[0045] The present invention provides a detection method for Longbishu capsules, comprising the following steps: according to the effective chemical components of 6 traditional Chinese medicines constituting Longbishu capsules, a network pharmacology analysis method is adopted to obtain a network pharmacology map of the compound traditional Chinese medicine of Longbishu capsules, and according to the network pharmacology map of the compound traditional Chinese medicine of Longbishu capsules, 8 pharmacologically active ingredients of the Longbishu capsules are obtained, wherein the 8 pharmacologically active ingredients are succinic acid, arachidonic acid, isorhamnetin, acacetin, kaempferol, quercetin, hederin and β-sitosterol; Longbishu capsules are extracted with a polar solvent, and the obtained extract is desolventized to obtain a sample to be tested; the sample to be tested is dissolved in an alcohol-water solvent, Obtain a sample solution to be tested; perform high performance liquid chromatography on the sample solution to obtain a liquid chromatogram of the sample solution to be tested, and obtain the peak areas corresponding to the eight pharmacologically active ingredients in the Longbishu Capsule from the liquid chromatogram of the sample solution to be tested; and then obtain the mass contents of the eight pharmacologically active ingredients in the Longbishu Capsule from a linear fitting curve or a linear regression equation of the mass concentrations of the eight pharmacologically active ingredients and the peak areas; the conditions for the high performance liquid chromatography detection include: the mobile phase includes a mobile phase A and a mobile phase B, the mobile phase A is a 0.2 v:v% formic acid aqueous solution, and the mobile phase B is acetonitrile; gradient elution is used, and the procedure of the gradient elution is as above. The detection method provided by the present invention adopts the network pharmacology analysis method to accurately determine the 8 pharmacologically active ingredients of Longbishu Capsules, and provides a high performance liquid chromatography detection method for the content of the pharmacologically active ingredients of Longbishu Capsules. By controlling the detection conditions of the high performance liquid chromatography, the 8 pharmacologically active ingredients of Longbishu Capsules can be accurately obtained, thereby being used as quality control indicators of Longbishu Capsules. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 This is the network pharmacology diagram of the compound Chinese medicine of Longbishu Capsule. Figure 1 The squares are Chinese medicinal materials, the circles are ingredients, the diamonds are targets, and the hexagons are common ingredients;
[0047] Figure 2 The chromatograms of the mixed standard solutions of succinic acid, arachidonic acid, isorhamnetin, acacetin, kaempferol, quercetin, hederin and β-sitosterol;
[0048] Figure 3 The chromatograms of succinic acid, arachidonic acid, isorhamnetin, acacetin, kaempferol, quercetin, hederin and β-sitosterol in the sample solution to be tested. DETAILED DESCRIPTION
[0049] The present invention provides a method for detecting Longbishu capsules, comprising the following steps:
[0050] According to the effective chemical components of the six traditional Chinese medicines constituting the Longbishu Capsule, a network pharmacology analysis method was used to obtain a network pharmacology map of the compound traditional Chinese medicine of the Longbishu Capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the Longbishu Capsule, eight pharmacologically active ingredients of the Longbishu Capsule were obtained, and the eight pharmacologically active ingredients were succinic acid, arachidonic acid, isorhamnetin, acacetin, kaempferol, quercetin, hederin and β-sitosterol.
[0051] Extracting the Longbishu capsule with a polar solvent, removing the solvent from the obtained extract to obtain a sample to be tested;
[0052] Dissolving the sample to be tested in an alcohol-water solvent to obtain a sample solution to be tested;
[0053] The sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to the eight pharmacologically active ingredients in the Longbishu Capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass contents of the eight pharmacologically active ingredients in the Longbishu Capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentrations and peak areas of the eight pharmacologically active ingredients;
[0054] The conditions for the HPLC detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.2 v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; gradient elution is adopted, and the procedure of the gradient elution is:
[0055] Retention time, minutes Mobile phase A, v:v% Mobile phase B, v:v% 0 10 90 2 15 85 5 16 84 8 20 80 9 45 55 10 10 90 .
[0056] In the present invention, unless otherwise specified, all preparation raw materials / components are commercially available products well known to those skilled in the art.
[0057] According to the effective chemical components of the six traditional Chinese medicines constituting the Longbishu capsule, the present invention adopts a network pharmacology analysis method to obtain a network pharmacology diagram of the compound traditional Chinese medicine of the Longbishu capsule, and obtains eight pharmacologically active ingredients of the Longbishu capsule according to the network pharmacology diagram of the compound traditional Chinese medicine of the Longbishu capsule, wherein the eight pharmacologically active ingredients are succinic acid, arachidonic acid, isorhamnetin, acacetin, kaempferol, quercetin, hederin and beta-sitosterol. In the present invention, the six traditional Chinese medicines constituting the Longbishu capsule include Psoralea corylifolia linn, Lygodii spora, Ambrum, Lysimachiae herba, Pseudobulbus cremastrae seupleiones and Leonuri herba. In the present invention, the specific implementation method of obtaining the network pharmacology map of the compound Chinese medicine of Longbishu Capsule by using the network pharmacology analysis method preferably includes:
[0058] Step 1: Active ingredient collection and screening
[0059] The invention uses a Chinese medicine system pharmacology database analysis platform (TCMSP) to retrieve effective chemical components of 6 traditional Chinese medicines in the composition of Longbishu capsules, and uses ADME parameters to screen out possible active drug molecules. The ADME parameters include: setting an oral bioavailability threshold (OB) ≥ 30%, a drug similarity threshold (DL) ≥ 0.18%, and other parameters are set by default. The traditional Chinese medicines that cannot be retrieved by TCMSP are screened for effective chemical components through the Chinese Medicine Integrated Pharmacology Research Platform v2.0 (TCMIP) and literature. SwissADME performs virtual screening of drug components and takes an intersection with BPH gene targets to obtain 32 effective chemical components of Longbishu capsules, including 6 psoralea corylifolia, 8 sea sand sand, 3 amber, 11 desmodium herba, 4 trillium, and 8 motherwort. Seven components are common components in two or more medicinal materials.
[0060] Step 2: Prediction, screening and cross-validation of active ingredient target proteins
[0061] The TCMSP database was used to predict and screen 32 active ingredients that met the criteria and corresponded to 237 target proteins. The CTD database was used to search for related genes using prostatic hyperplasia as a keyword, and the genes ranked above 30 in the Inference score were intersected with the target proteins predicted by the TCMSP database, resulting in 161 intersection-related target proteins.
[0062] Step 3: GO functional annotation and KEGG pathway enrichment analysis
[0063] The 161 target proteins were analyzed by GO functional annotation and KEGG pathway enrichment in Metascape. GO functional annotation showed that the target genes were involved in the regulation of cell death and apoptosis signaling pathways, the response to hormones, cells to lipids, to inorganic substances, cells to organic cyclic compounds, and to external stimuli. KEGG enrichment showed that these reaction processes may occur through pathways such as cancer pathways, lipids and atherosclerosis, fluid shear stress and atherosclerosis, the role of AGE-RAGE signaling pathways in diabetic complications, chemical carcinogens-receptor activation, and MAPK signaling pathways.
[0064] Step 4: Component-target protein interaction analysis
[0065] The 161 target proteins obtained were uploaded to the STRING database for protein-protein interaction enrichment analysis. The species was set to "Homo sapiens", free nodes were hidden, and the minimum required interaction score was set to the highest confidence (0.900) for PPI network diagram construction. Cytoscape3.9.1 was used to further analyze and optimize the PPI network diagram. A network interaction diagram consisting of 137 nodes and 614 edges was obtained (node size, color depth, and connection density represent the importance of target genes). The top 10 core genes with the highest degree values were: SRC, TP53, MAPK1, AKT1, RELA, TNF, FOS, ESR1, MAPK14, IL6 and their interactions.
[0066] Step 5: Construction of network pharmacology of compound Chinese medicine
[0067] The corresponding genes of the 237 target proteins obtained by screening were imported into Cytoscape 3.9.1 software to draw a network diagram of traditional Chinese medicine compound, namely the "herbal medicine-ingredient-target" network diagram. The network has a total of 199 nodes and 705 relationships, including 6 drug nodes (traditional Chinese medicine), 32 chemical component nodes, and 161 target protein nodes of Longbishu Capsule. The chemical components with the top 8 degree values are: quercetin (CAS: 117-39-5), kaempferol (CAS: 520-18-3), isorhamnetin (CAS: 480-19-3), acacia (CAS: 480-44-4), β-sitosterol (CAS: 83-46-5), arachidonic acid (CAS: 93444-49-6), succinic acid (CAS: 110-15-6), and hederagenine (CAS: 474-58-8). These components are the core control components of the efficacy of this medicinal material.
[0068] After obtaining the eight pharmacologically active ingredients of the Longbishu capsule, the present invention extracts the Longbishu capsule with a polar solvent, and the obtained extract is desolventized to obtain a sample to be tested. In the present invention, the polar solvent used for the extraction is preferably a low-carbon alcohol or a low-carbon alcohol aqueous solution, and the low-carbon alcohol preferably includes methanol or ethanol, and more preferably methanol. The low-carbon alcohol aqueous solution preferably includes a methanol aqueous solution or an ethanol aqueous solution, and more preferably an ethanol aqueous solution. The mass percentage of low-carbon alcohol in the low-carbon alcohol aqueous solution is preferably 80%. The solid-liquid ratio of the Longbishu capsule and the polar solvent is preferably 1: (15-20); the extraction is carried out under heating reflux conditions or under ultrasonic conditions. When the extraction is carried out under heating reflux conditions, the extraction time is preferably 3-4h, and the extraction is preferably carried out in a Soxhlet extractor. When the extraction is carried out under ultrasonic conditions, the number of extractions is preferably 2 times, and the time of each extraction is preferably 30-40min. The ultrasonic conditions include: the ultrasonic power is preferably 100-150W, and the ultrasonic frequency is preferably 40-50kHz. After the extraction, an extract liquid is obtained. In the present invention, the extract liquid is preferably subjected to solid-liquid separation to obtain an extract liquid. The solid-liquid separation is preferably performed by filtration. The solvent removal is preferably performed by evaporation. The solvent removal is preferably performed in a rotary evaporator.
[0069] After obtaining the sample to be tested, the present invention dissolves the sample to be tested in an alcohol-water solvent to obtain a sample solution. In the present invention, the alcohol-water solvent for dissolving the sample to be tested is preferably a methanol aqueous solution, and the mass percentage of methanol in the methanol aqueous solution is preferably 80wt%. After the sample to be tested is dissolved in the alcohol-water solvent, an initial sample solution to be tested is obtained. The present invention preferably removes impurities from the initial sample solution to obtain the sample solution to be tested. The specific embodiment of the removal of impurities is preferably membrane filtration, and the membrane filtration preferably uses a nylon membrane, and the pore size of the nylon membrane is preferably 0.22μm.
[0070] After obtaining the test sample solution, the present invention performs high performance liquid chromatography on the test sample solution to obtain a liquid chromatogram of the test sample solution, and obtains the peak areas corresponding to the eight pharmacologically active ingredients in the Longbishu capsule from the liquid chromatogram of the test sample solution; and then obtains the mass contents of the eight pharmacologically active ingredients in the Longbishu capsule from a linear fitting curve or a linear regression equation of the mass concentrations and peak areas of the eight pharmacologically active ingredients.
[0071] In the present invention, the conditions for the HPLC detection preferably include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.2 v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; gradient elution is adopted, and the procedure of the gradient elution is:
[0072]
[0073]
[0074] In the present invention, the meaning of the gradient elution procedure is:
[0075] From 0 min to 2 min, the volume percentage of mobile phase A changed linearly from 10% to 15%;
[0076] From 2 min to 5 min, the volume percentage of mobile phase A changed linearly from 15% to 16%;
[0077] From 5 min to 8 min, the volume percentage of mobile phase A changed linearly from 16% to 20%;
[0078] From 8 min to 9 min, the volume percentage of mobile phase A changed linearly from 20% to 45%;
[0079] From 9 min to 10 min, the volume percentage of mobile phase A changed linearly from 45% to 10%.
[0080] In the present invention, the conditions for the HPLC detection preferably include: the column temperature is preferably 30°C, the flow rate of the mobile phase is preferably 1 mL·min -1 .
[0081] In the present invention, the conditions for the HPLC detection preferably also include: the detection wavelength is preferably 280 nm.
[0082] In the present invention, in the liquid chromatography detection, the injection volume of the sample solution to be tested is preferably 5 μL.
[0083] In the present invention, the chromatographic column used in the high performance liquid chromatography is preferably a reverse phase C-18 column; the length of the chromatographic column is 100 mm, the inner diameter is 4.6 mm, and the size of the filler is 1.8 μm.
[0084] In the present invention, the method for obtaining the linear fitting curve and the linear regression equation of the mass concentration and peak area of the eight pharmacologically active ingredients preferably comprises the following steps:
[0085] Dissolving 8 pharmacologically active ingredients in alcohol-water solvents respectively to obtain a series of standard solutions of 8 pharmacologically active ingredients with different mass concentrations respectively, subjecting the series of standard solutions of 8 pharmacologically active ingredients with different mass concentrations to high performance liquid chromatography detection respectively to obtain a series of liquid chromatograms of different mass concentrations corresponding to the 8 pharmacologically active ingredients respectively, and obtaining the liquid chromatographic retention times and linear ranges of 8 pharmacologically active ingredients from the series of liquid chromatograms of different mass concentrations corresponding to the 8 pharmacologically active ingredients respectively;
[0086] A series of mixed standard solutions with different mass concentrations are subjected to high performance liquid chromatography to obtain liquid chromatograms of a series of mixed standard solutions with different mass concentrations, wherein the mixed standard solutions include 8 pharmacologically active ingredients and an alcohol-water solvent; a linear fitting curve of mass concentrations and peak areas of the 8 pharmacologically active ingredients in the mixed standard solutions is obtained from the mass concentrations of the 8 pharmacologically active ingredients in the series of mixed standard solutions with different mass concentrations, the liquid chromatograms of the mixed standard solutions, and the liquid chromatographic retention times of the 8 pharmacologically active ingredients;
[0087] The linear regression equations of the mass concentrations and peak areas of the eight pharmacologically active ingredients in the mixed standard solution were obtained from the linear fitting curves of the mass concentrations and peak areas of the eight pharmacologically active ingredients in the mixed standard solution.
[0088] In the present invention, when a series of standard solutions of 8 pharmacologically active ingredients with different mass concentrations are subjected to HPLC detection, and a series of mixed standard solutions with different mass concentrations are subjected to HPLC detection, the HPLC detection method adopted is the same as the HPLC detection method of the sample solution to be tested in the above text, and will not be described one by one here.
[0089] In the present invention, the linear regression equation of the mass concentration and peak area of the eight pharmacologically active ingredients in the mixed standard solution includes:
[0090] The linear regression equation of the mass concentration and peak area of succinic acid is shown in Formula 1:
[0091] Y = 22450X + 5 Formula 1;
[0092] The linear regression equation of the mass concentration and peak area of arachidonic acid is shown in Formula 2:
[0093] Y = 11447X-10 Formula 2;
[0094] The linear regression equation of the mass concentration and peak area of isorhamnetin is shown in Formula 3:
[0095] Y = 10985X + 4 Formula 3;
[0096] The linear regression equation of the mass concentration and peak area of acacetin is shown in Formula 4:
[0097] Y = 11327X + 7 Formula 4;
[0098] The linear regression equation of the mass concentration and peak area of kaempferol is shown in Formula 5:
[0099] Y = 13854X-13 Formula 5;
[0100] The linear regression equation of the mass concentration and peak area of quercetin is shown in Formula 6:
[0101] Y = 12854X + 2 Formula 6;
[0102] The linear regression equation of the mass concentration and peak area of the ivy extract is shown in Formula 7:
[0103] Y=9793.5X-6 Formula 7;
[0104] The linear regression equation of the mass concentration and peak area of the β-sitosterol is shown in Formula 8:
[0105] Y = 21267X + 11 Formula 8;
[0106] In Formulas 1 to 8: X represents the mass concentration of succinic acid, the mass concentration of arachidonic acid, the mass concentration of isorhamnetin, the mass concentration of acacetin, the mass concentration of kaempferol, the mass concentration of quercetin, the mass concentration of hederin, and the mass concentration of β-sitosterol in the mixed standard solution, respectively;
[0107] In Formulas 1 to 8, Y represents the peak area of succinic acid, the peak area of arachidonic acid, the peak area of isorhamnetin, the peak area of acacetin, the peak area of kaempferol, the peak area of quercetin, the peak area of hederin, and the peak area of β-sitosterol in the liquid chromatogram of the mixed standard solution, respectively.
[0108] In the present invention, the linear regression equations of the mass concentrations and peak areas of the eight pharmacologically active ingredients in the mixed standard solution are shown in Table 1. In Table 1, 1 represents succinic acid; 2 represents arachidonic acid; 3 represents isorhamnetin; 4 represents acacetin; 5 represents kaempferol; 6 represents quercetin; 7 represents hederagenin; and 8 represents β-sitosterol.
[0109] Table 18 linear equations and linear ranges of standard substances
[0110]
[0111] In order to further illustrate the present invention, the technical solutions provided by the present invention are described in detail below in conjunction with embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0112] Example 1
[0113] In this embodiment, according to the effective chemical components of the six traditional Chinese medicines constituting the Longbishu capsule, a network pharmacology analysis method is used to obtain the network pharmacology map of the compound traditional Chinese medicine of the Longbishu capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the Longbishu capsule, eight kinds of pharmacologically active ingredients of the Longbishu capsule are obtained, and the eight kinds of pharmacologically active ingredients are succinic acid, arachidonic acid, isorhamnetin, acacetin, kaempferol, quercetin, hederin and β-sitosterol. Among them, the six traditional Chinese medicines constituting the Longbishu capsule include Psoralea corylifolia linn, Lygodii Spora, Ambrum, Lysimachiae Herba, Pseudobulbus Cremastrae SeuPleiones and Leonuri Herba. In the embodiment, the specific implementation method of obtaining the network pharmacology map of the compound Chinese medicine of Longbishu Capsule by using the network pharmacology analysis method includes:
[0114] Step 1: Active ingredient collection and screening
[0115] In this example, the effective chemical components of the six traditional Chinese medicines in the composition of Longbishu Capsule were retrieved through the Traditional Chinese Medicine System Pharmacology Database Analysis Platform (TCMSP), and possible active drug molecules were screened out using ADME parameters. The ADME parameters included: setting an oral bioavailability threshold (OB) ≥ 30%, a drug similarity threshold (DL) ≥ 0.18%, and other parameters were set as default. The traditional Chinese medicines that could not be retrieved by TCMSP were screened for effective chemical components through the Traditional Chinese Medicine Integrated Pharmacology Research Platform v2.0 (TCMIP) and literature. SwissADME performed virtual screening of drug components and took the intersection with the BPH gene target, and 32 effective chemical components of Longbishu Capsule were obtained, including 6 Psoralea corylifolia, 8 Lygodium japonicum, 3 Amber, 11 Lysimachia chinensis, 4 Psoralea corylifolia, and 8 Leonurus japonicus. Seven components were common components in two or more medicinal materials.
[0116] Step 2: Prediction, screening and cross-validation of active ingredient target proteins
[0117] The TCMSP database was used to predict and screen 32 active ingredients that met the criteria and corresponded to 237 target proteins. The CTD database was used to search for related genes using prostatic hyperplasia as a keyword, and the genes ranked above 30 in the Inference score were intersected with the target proteins predicted by the TCMSP database, resulting in 161 intersection-related target proteins.
[0118] Step 3: GO functional annotation and KEGG pathway enrichment analysis
[0119] The 161 target proteins were analyzed by GO functional annotation and KEGG pathway enrichment in Metascape. GO functional annotation showed that the target genes were involved in the regulation of cell death and apoptosis signaling pathways, the response to hormones, cells to lipids, to inorganic substances, cells to organic cyclic compounds, and to external stimuli. KEGG enrichment showed that these reaction processes may occur through pathways such as cancer pathways, lipids and atherosclerosis, fluid shear stress and atherosclerosis, the role of AGE-RAGE signaling pathways in diabetic complications, chemical carcinogens-receptor activation, and MAPK signaling pathways.
[0120] Step 4: Component-target protein interaction analysis
[0121] The 161 target proteins obtained were uploaded to the STRING database for protein-protein interaction enrichment analysis. The species was set to "Homo sapiens", free nodes were hidden, and the minimum required interaction score was set to the highest confidence (0.900) for PPI network diagram construction. Cytoscape3.9.1 was used to further analyze and optimize the PPI network diagram. A network interaction diagram consisting of 137 nodes and 614 edges was obtained (node size, color depth, and connection density represent the importance of target genes). The top 10 core genes with the highest degree values were: SRC, TP53, MAPK1, AKT1, RELA, TNF, FOS, ESR1, MAPK14, IL6 and their interactions.
[0122] Step 5: Construction of network pharmacology of compound Chinese medicine
[0123] The corresponding genes of the 237 target proteins obtained by screening were imported into Cytoscape 3.9.1 software to draw a network diagram of traditional Chinese medicine compound, namely the "herbal medicine-ingredient-target" network diagram. The network has a total of 199 nodes and 705 relationships, including 6 drug nodes (traditional Chinese medicine), 32 chemical component nodes, and 161 target protein nodes of Longbishu Capsule. The chemical components with the top 8 degree values obtained through analysis are: quercetin (CAS: 117-39-5), kaempferol (CAS: 520-18-3), isorhamnetin (CAS: 480-19-3), acacia (CAS: 480-44-4), β-sitosterol (CAS: 83-46-5), arachidonic acid (CAS: 93444-49-6), succinic acid (CAS: 110-15-6), and hederain (CAS: 474-58-8). These components are the core control components of the efficacy of this medicinal material. The unique effective chemical components of the 6 Chinese medicinal materials in the Longbishu Capsule in this embodiment are shown in Table 2, and the common chemical components of the 6 Chinese medicinal materials in the Longbishu Capsule are shown in Table 3. The network pharmacology diagram of the compound Chinese medicine of the Longbishu Capsule obtained in this embodiment is shown in Figure 1 As shown, Figure 1 The squares are Chinese medicinal materials, the circles are ingredients, the diamonds are targets, and the hexagons are common ingredients.
[0124] Table 2 Unique active chemical components in the six medicinal materials of Longbishu Capsule
[0125]
[0126] Table 3 Chemical components in the six medicinal materials of Longbishu Capsules
[0127]
[0128]
[0129] Standard preparation:
[0130] Preparation of a single standard solution: Accurately weigh a certain amount of standard substance (0.1-0.5 mg), add 5 mL of 80% methanol aqueous solution to a 10 mL volumetric flask, fully dissolve and dilute to 10 mL to obtain a standard solution with a determined concentration (0.02-0.1 mg / mL). When using, 0.1, 0.25, 0.5, 1, 2 mL of the mother solution of the standard solution can be added to a 10 mL volumetric flask, and 80 wt% methanol aqueous solution can be diluted to the scale to obtain 100, 75, 50, 10, 5 times diluted standard solutions. Liquid chromatography retention time is qualitative, and peak area-concentration linear relationship analysis is quantitative.
[0131] Preparation of mixed standard solution: Pipette 0.1 mL of each standard substance solution of known concentration, add to a 10 mL volumetric flask, dilute to the mark with 80 wt% methanol aqueous solution, and obtain a 100-fold diluted mixed standard substance solution (the mixed standard solution can be prepared in various concentrations and proportions according to the given method. The retention time obtained by a single standard substance is slightly different from the retention time obtained by the mixed standard substance, so the mixed standard substance spectrum is used to qualitatively and quantitatively analyze the sample). Liquid chromatography is used to detect the 8 active ingredients in the mixed standard solution, and a liquid chromatogram of the mixed standard solution is obtained, as shown in FIG. Figure 2 As shown, Figure 2 In Chinese: 1 represents succinic acid; 2 represents arachidonic acid; 3 represents isorhamnetin; 4 represents acacetin; 5 represents kaempferol; 6 represents quercetin; 7 represents hederin; 8 represents β-sitosterol.
[0132] A linear fitting curve of mass concentration and peak area of the 8 pharmacologically active ingredients in the mixed standard solution is obtained from the mass concentration of the 8 pharmacologically active ingredients in the mixed standard solution, the liquid chromatogram of the mixed standard solution, and the liquid chromatographic retention time of the 8 pharmacologically active ingredients; a linear regression equation of mass concentration and peak area of the 8 pharmacologically active ingredients in the mixed standard solution is obtained from the linear fitting curve of mass concentration and peak area of the 8 pharmacologically active ingredients in the mixed standard solution. Details of the linear regression equation are shown in Table 1.
[0133] 30 g of Longbishu Capsules (commercially available product) were added to a 1000 mL Soxhlet extractor, and an ethanol aqueous solution (wherein the mass percentage of ethanol was 80%) was added at a material-liquid mass ratio of 20:1. The mixture was heated under reflux for 4 hours, the insoluble matter was removed by filtration, and the solvent was removed from the mixed solution by a rotary evaporator to obtain a sample to be tested.
[0134] The sample to be tested (0.1-0.5 mg) was first dissolved in 5 mL of 80 wt% methanol aqueous solution, then the volume was fixed to 10 mL, and filtered through a 0.22 m nylon membrane to obtain a sample solution to be tested.
[0135] After obtaining the sample solution to be tested, the sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, such as Figure 3 As shown, Figure 3 In: 1 represents succinic acid; 2 represents arachidonic acid; 3 represents isorhamnetin; 4 represents acacetin; 5 represents kaempferol; 6 represents quercetin; 7 represents hederin; 8 represents β-sitosterol. The peak areas corresponding to the 8 pharmacologically active ingredients in the Longbishu capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass contents of the 8 pharmacologically active ingredients in the Longbishu capsule are obtained from the linear fitting curve or linear regression equation of the mass concentration and peak area of the 8 pharmacologically active ingredients.
[0136] In the embodiment, the conditions of the above-mentioned high performance liquid chromatography detection are the same, including: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.2v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; gradient elution is adopted, the column temperature is preferably 30°C, and the flow rate of the mobile phase is preferably 1mL·min -1 The detection wavelength is preferably 280 nm, the injection volume of the sample solution to be tested is preferably 5 μL, the chromatographic column used in the HPLC is a reverse phase C-18 column; the length of the chromatographic column is 100 mm, the inner diameter is 4.6 mm (Agilent Technologies, Beijing, China), and the size of the filler is 1.8 μm. The gradient elution procedure is:
[0137] Retention time, minutes Mobile phase A, v:v% Mobile phase B, v:v% 0 10 90 2 15 85 5 16 84 8 20 80 9 45 55 10 10 90 .
[0138] In this example, the mass contents (mg / g) of 8 kinds of pharmacologically active ingredients in Longbishu Capsules are determined as follows: succinic acid (0.0079), arachidonic acid (0.0105), isorhamnetin (0.0035), acacetin (0.0017), kaempferol (0.0019), quercetin (0.0028), hederafinil (0.0354), and β-sitosterol (0.0141).
[0139] Test Case
[0140] Activity analysis evaluation:
[0141] Preparation of Longbishu Capsule Control: Take 10g of Longbishu Capsule powder, add 150mL of methanol, ultrasonically (power 100W, frequency 40kHz) for 30min, extract twice, and filter the solution under reduced pressure. Add 100mL of anhydrous ethanol to the filter residue, ultrasonically extract twice, and filter under reduced pressure. Combine the filtrates, evaporation and dry at room temperature, add 10mL of DMEM (high glucose culture medium) culture medium, and filter through a 0.22μm microporous filter membrane after ultrasonic dissolution to obtain a standard control solution, which is stored at -20℃ for use. When used, dilute with DMEM culture medium to 0.5 times, 0.25 times, and 0.1 times the concentration of the control solution.
[0142] Preparation of drug equivalent solution: Take 8 core drug control components, weigh samples according to the content level of each substance in 10 grams of original drug, add 10mL DMEM culture medium, and filter through a 0.22μm microporous filter membrane after ultrasonic dissolution to obtain drug equivalent solution, which is stored at -20℃ for later use. When using, dilute with DMEM culture medium to 0.5 times, 0.25 times, and 0.1 times the concentration of drug equivalent solution.
[0143] The original solution of Longbishu capsule control substance and its pharmacodynamic equivalent solution were used to treat dihydrotestosterone-induced WPMY-1 cells. The levels of PSA, DHT and E2 in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (892 (890) ng / mL, 5.7 (5.7) nM / L, 43.0 (42.9) pM / L). The NO content and NOS activity of WPMY-1 cells were detected by kit (6.5 (6.5) UM, 0.0057 (0.0058) Ug / mL). The protein expression levels of ERα, Bax, Bcl-2 and CyclinD1 in WPMY-1 cells were detected by Western Blot (0.68 (0.67), 1.57 (1.58), 0.46 (0.45), 0.21 (0.22)). The results showed that there were no significant differences in the parameters.
[0144] WPMY-1 cells induced by dihydrotestosterone were treated with 0.5 times the control and 0.5 times the drug equivalent solution of Longbishu Capsule. The PSA, DHT and E2 levels in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (854 (858) ng / mL, 5.4 (5.4) nM / L, 42.5 (42.4) pM / L)). The NO content and NOS activity of WPMY-1 cells were detected by kit (6.0 (5.9) UM, 0.0052 (0.0053) Ug / mL)). The protein expression levels of ERα, Bax, Bcl-2 and Cyclin D1 in WPMY-1 cells were detected by Western Blot (0.72 (0.72), 1.23 (1.22), 0.57 (0.56), 0.38 (0.39)). The results showed that there were no significant differences in the parameters.
[0145] WPMY-1 cells induced by dihydrotestosterone were treated with 0.25 times the control and 0.25 times the drug equivalent solution of Longbishu Capsule. The PSA, DHT and E2 levels in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (791 (790) ng / mL, 5.2 (5.2) nM / L, 41.6 (41.5) pM / L). The NO content and NOS activity of WPMY-1 cells were detected by kit (5.5 (5.5) UM, 0.0044 (0.0045) Ug / mL)). The protein expression levels of ERα, Bax, Bcl-2 and Cyclin D1 in WPMY-1 cells were detected by Western Blot (0.77 (0.77), 1.05 (1.08), 0.82 (0.81), 0.75 (0.76)). The results showed that there were no significant differences in the parameters.
[0146] WPMY-1 cells induced by dihydrotestosterone were treated with 0.1 times control and 0.1 times drug equivalent solution of Longbishu Capsule. The levels of PSA, DHT and E2 in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (710 (714) ng / mL, 4.3 (4.3) nM / L, 40.2 (40.2) pM / L)). The NO content and NOS activity of WPMY-1 cells were detected by kit (5.2 (5.2) UM, 0.0038 (0.0039) Ug / mL)). The protein expression levels of ERα, Bax, Bcl-2 and Cyclin D1 in WPMY-1 cells were detected by Western Blot (0.85 (0.87), 0.82 (0.81), 0.93 (0.94), 0.88 (0.89)). The results showed that there were no significant differences in the parameters.
[0147] It can be seen from the above embodiments that the detection method provided by the present invention uses the network pharmacology analysis method to accurately determine the 8 pharmacologically active ingredients of Longbishu Capsules, and provides a high performance liquid chromatography detection method for the content of pharmacologically active ingredients of Longbishu Capsules. By controlling the detection conditions of high performance liquid chromatography, the 8 pharmacologically active ingredients of Longbishu Capsules can be accurately obtained, thereby being used as quality control indicators of Longbishu Capsules.
[0148] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. Other embodiments can be obtained based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A method for detecting Longbishu Capsules, characterized in that: The following steps are involved: According to the effective chemical components of the six traditional Chinese medicines constituting the Longbishu Capsule, a network pharmacology analysis method was used to obtain a network pharmacology map of the compound traditional Chinese medicine of the Longbishu Capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the Longbishu Capsule, eight pharmacologically active ingredients of the Longbishu Capsule were obtained, and the eight pharmacologically active ingredients were succinic acid, arachidonic acid, isorhamnetin, acacetin, kaempferol, quercetin, hederin and β-sitosterol. Extracting the Longbishu capsule with a polar solvent, removing the solvent from the obtained extract to obtain a sample to be tested; Dissolving the sample to be tested in an alcohol-water solvent to obtain a sample solution to be tested; The sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to the eight pharmacologically active ingredients in the Longbishu Capsule are obtained from the liquid chromatogram of the sample solution to be tested; Then, the mass contents of the eight pharmacologically active ingredients in the Longbishu capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentration and peak area of the eight pharmacologically active ingredients; The conditions for the HPLC detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.2 v:v% formic acid aqueous solution, and mobile phase B is acetonitrile; Gradient elution was used, and the procedure of the gradient elution was as follows: 。 2. The detection method according to claim 1, characterized in that: The conditions for the HPLC detection also include: column temperature of 30°C, flow rate of the mobile phase of 1 mL min -1 .
3. The detection method according to claim 1 or 2, characterized in that: The conditions for the high performance liquid chromatography detection also include: the detection wavelength is 280nm.
4. The detection method according to claim 1, characterized in that: The alcohol-water solvent for dissolving the sample to be tested is a methanol-water solution, and the mass percentage of methanol in the methanol-water solution is 80wt%.
5. The detection method according to claim 1 or 4, characterized in that: In the liquid chromatography detection, the injection volume of the sample solution to be tested is 5 μL.
6. The detection method according to claim 1, characterized in that: The polar solvent used for the extraction is low-carbon alcohol or low-carbon alcohol aqueous solution, the low-carbon alcohol includes methanol or ethanol, and the low-carbon alcohol aqueous solution includes methanol aqueous solution or ethanol aqueous solution; the mass percentage of low-carbon alcohol in the low-carbon alcohol aqueous solution is 80%.
7. The detection method according to claim 1 or 6, characterized in that: The solid-liquid ratio of the Longbishu capsule to the polar solvent is 1:(15-20); the extraction is carried out under heating reflux conditions or under ultrasonic conditions.
8. The detection method according to claim 1, characterized in that: The method for obtaining the linear fitting curve and the linear regression equation of the mass concentration and peak area of the eight pharmacologically active ingredients comprises the following steps: Dissolving 8 pharmacologically active ingredients in alcohol-water solvents respectively to obtain a series of standard solutions of 8 pharmacologically active ingredients with different mass concentrations respectively, subjecting the series of standard solutions of 8 pharmacologically active ingredients with different mass concentrations to high performance liquid chromatography detection respectively to obtain a series of liquid chromatograms of different mass concentrations corresponding to the 8 pharmacologically active ingredients respectively, and obtaining the liquid chromatographic retention times and linear ranges of 8 pharmacologically active ingredients from the series of liquid chromatograms of different mass concentrations corresponding to the 8 pharmacologically active ingredients respectively; A series of mixed standard solutions with different mass concentrations are subjected to high performance liquid chromatography to obtain liquid chromatograms of a series of mixed standard solutions with different mass concentrations, wherein the mixed standard solutions include 8 pharmacologically active ingredients and an alcohol-water solvent; a linear fitting curve of mass concentrations and peak areas of the 8 pharmacologically active ingredients in the mixed standard solutions is obtained from the mass concentrations of the 8 pharmacologically active ingredients in the series of mixed standard solutions with different mass concentrations, the liquid chromatograms of the mixed standard solutions, and the liquid chromatographic retention times of the 8 pharmacologically active ingredients; The linear regression equations of the mass concentrations and peak areas of the eight pharmacologically active ingredients in the mixed standard solution were obtained from the linear fitting curves of the mass concentrations and peak areas of the eight pharmacologically active ingredients in the mixed standard solution.
9. The detection method according to claim 1 or 8, characterized in that: The linear regression equations of mass concentration and peak area of the eight active ingredients in the mixed standard solution include: The linear regression equation of the mass concentration and peak area of succinic acid is shown in Formula 1: Y22450X+5 formula 1; The linear regression equation of the mass concentration and peak area of arachidonic acid is shown in Formula 2: Y211447X-10 formula 2; The linear regression equation of the mass concentration and peak area of isorhamnetin is shown in Formula 3: Y=110985X+4Formula 3; The linear regression equation of the mass concentration and peak area of acacetin is shown in Formula 4: Y = 111327X + 7 Formula 4; The linear regression equation of the mass concentration and peak area of kaempferol is shown in Formula 5: Y = 13854X-13 Formula 5; The linear regression equation of the mass concentration and peak area of quercetin is shown in Formula 6: Y = 12854X + 2 Formula 6; The linear regression equation of the mass concentration and peak area of the hederafilin is shown in Formula 7: Y=9793.5X-6 Formula 7; The linear regression equation of the mass concentration and peak area of the β-sitosterol is shown in Formula 8: Y = 221267X + 11 Formula 8; In Formulas 1 to 8: X represents the mass concentration of succinic acid, the mass concentration of arachidonic acid, the mass concentration of isorhamnetin, the mass concentration of acacetin, the mass concentration of kaempferol, the mass concentration of quercetin, the mass concentration of hederin, and the mass concentration of β-sitosterol in the mixed standard solution, respectively; In Formulas 1 to 8, Y represents the peak area of succinic acid, the peak area of arachidonic acid, the peak area of isorhamnetin, the peak area of acacetin, the peak area of kaempferol, the peak area of quercetin, the peak area of hederin, and the peak area of β-sitosterol in the liquid chromatogram of the mixed standard solution, respectively.
10. The detection method according to claim 1, characterized in that: The chromatographic column used in the high performance liquid chromatography is a reverse phase C-18 column; the length of the chromatographic column is 100 mm, the inner diameter is 4.6 mm, and the size of the filler is 1.8 μm.
